Search

Your search keyword '"Shibayama H"' showing total 452 results
Start Over Author "Shibayama H"
452 results on '"Shibayama H"'

1. Latest results of the OPERA experiment on nu-tau appearance in the CNGS neutrino beam

Author

N. Agafonova, A. Alexandrov, A. Anokhina, S. Aoki, A. Ariga, T. Ariga, A. Bertolin, C. Bozza, R. Brugnera, A. Buonaura, S. Buontempo, M. Chernyavskiy, A. Chukanov, L. Consiglio, N. D'Ambrosio, G. De Lellis, M. De Serio, P. del Amo Sanchez, A. Di Crescenzo, D. Di Ferdinando, N. Di Marco, S. Dmitrievsky, M. Dracos, D. Duchesneau, S. Dusini, T. Dzhatdoev, J. Ebert, A. Ereditato, J. Favier, R. A. Fini, F. Fornari, T. Fukuda, G. Galati, A. Garfagnini, V. Gentile, J. Goldberg, S. Gorbunov, Y. Gornushkin, G. Grella, A. M. Guler, C. Gustavino, C. Hagner, T. Hara, T. Hayakawa, A. Hollnagel, K. Ishiguro, A. Iuliano, K. Jakovcic, C. Jollet, C. Kamiscioglu, M. Kamiscioglu, S. H. Kim, N. Kitagawa, B. Klicek, K. Kodama, M. Komatsu, U. Kose, I. Kreslo, F. Laudisio, A. Lauria, A. Longhin, P. Loverre, M. Malenica, A. Malgin, G. Mandrioli, T. Matsuo, V. Matveev, N. Mauri, E. Medinaceli, A. Meregaglia, S. Mikado, M. Miyanishi, F. Mizutani, P. Monacelli, M. C. Montesi, K. Morishima, M. T. Muciaccia, N. Naganawa, T. Naka, M. Nakamura, T. Nakano, K. Niwa, S. Ogawa, A. Olchevsky, N. Okateva, K. Ozaki, A. Paoloni, L. Paparella, B. D. Park, L. Pasqualini, A. Pastore, L. Patrizii, H. Pessard, C. Pistillo, D. Podgrudkov, N. Polukhina, M. Pozzato, F. Pupilli, M. Roda, T. Roganova, H. Rokujo, G. Rosa, O. Ryazhskaya, A. Sadovsky, O. Sato, A. Schembri, I. Shakiryanova, T. Shchedrina, E. Shibayama, H. Shibuya, T. Shiraishi, S. Simone, C. Sirignano, G. Sirri, A. Sotnikov, M. Spinetti, L. Stanco, N. Starkov, S. M. Stellacci, M. Stipcevic, P. Strolin, S. Takahashi, M. Tenti, F. Terranova, V. Tioukov, S. Tufanli, A. Ustyuzhanin, S. Vasina, P. Vilain, E. Voevodina, L. Votano, J. L. Vuilleumier, G. Wilquet, B. Wonsak, C. S. Yoon

Subjects
Physics, QC1-999
Abstract

OPERA is a long-baseline experiment designed to search for $\nu_{\mu}\to\nu_{\tau}$ oscillations in appearance mode. It was based at the INFN Gran Sasso laboratory (LNGS) and took data from 2008 to 2012 with the CNGS neutrino beam from CERN. After the discovery of $\nu_\tau$ appearance in 2015, with $5.1\sigma$ significance, the criteria to select $\nu_\tau$ candidates have been extended and a multivariate approach has been used for events identification. In this way the statistical uncertainty in the measurement of the oscillation parameters and of $\nu_\tau$ properties has been improved. Results are reported.

Published
2019
Full Text
View/download PDF

2. P1007: PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA

Author

Kirito, K., primary, Edahiro, Y., additional, Ohishi, K., additional, Gotoh, A., additional, Takenaka, K., additional, Shibayama, H., additional, Shimizu, T., additional, Usuki, K., additional, Shimoda, K., additional, Ito, M., additional, VanWart, S. A., additional, Zagrijtschuk, O., additional, Qin, A., additional, Kawase, H., additional, Miyachi, N., additional, Sato, T., additional, and Komatsu, N., additional

Published
2022
Full Text
View/download PDF

3. A PHASE 2B OPEN‐LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HBI‐8000 (TUCIDINOSTAT) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA (PTCL)

Author

Kim, W. S., primary, Rai, S., additional, Ando, K., additional, Choi, I., additional, Izutsu, K., additional, Tsukamoto, N., additional, Yokoyama, M., additional, Tsukasaki, K., additional, Kuroda, J., additional, Ando, J., additional, Hidaka, M., additional, Koh, Y., additional, Shibayama, H., additional, Uchida, T., additional, Yang, D. H., additional, Ishitsuka, K., additional, Ishizawa, K., additional, Kim, J. S., additional, Lee, H. G., additional, Minami, H., additional, Eom, H. S., additional, Nagai, H., additional, Kurosawa, M., additional, Lee, J. H., additional, Lee, W. S., additional, Shindo, T., additional, Yoon, D. H., additional, Yoshida, S., additional, Gillings, M., additional, Onogi, H., additional, and Tobinai, K., additional

Published
2021
Full Text
View/download PDF

4. A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUCIDINOSTAT (HBI‐8000) IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY ADULT T‐CELL LEUKEMIA‐LYMPHOMA (ATL)

Author

Izutsu, K., primary, Utsunomiya, A., additional, Jo, T., additional, Yoshida, S., additional, Ando, K., additional, Choi, I., additional, Imaizumi, Y., additional, Kato, K., additional, Kurosawa, M., additional, Kusumoto, S., additional, Miyagi, T., additional, Ohtsuka, E., additional, Sasaki, O., additional, Shibayama, H., additional, Shimoda, K., additional, Takamatsu, Y., additional, Takano, K., additional, Tsukasaki, K., additional, Makita, S., additional, Yonekura, K., additional, Taguchi, J., additional, Gillings, M., additional, Onogi, H., additional, and Tobinai, K., additional

Published
2021
Full Text
View/download PDF

14. THE INFLUENCE OF TUMOR IMMUNE MICROENVIRONMENT AND TUMOR IMMUNITY ON THE PATHOGENESIS, TREATMENT AND PROGNOSIS OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD)

Author

Saito, H., primary, Shibayama, H., additional, Miyoshi, H., additional, Toda, J., additional, Kusakabe, S., additional, Ichii, M., additional, Fujita, J., additional, Fukushima, K., additional, Yokota, T., additional, Maeda, T., additional, Mizuki, M., additional, Oritani, K., additional, Seto, M., additional, Ohshima, K., additional, and Kanakura, Y., additional

Published
2019
Full Text
View/download PDF

15. PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Author

Murai, K., primary, Kimura, S., additional, Imagawa, J., additional, Hino, M., additional, Kitawaki, T., additional, Okada, M., additional, Tanaka, H., additional, Shindo, M., additional, Kumagai, T., additional, Ikezoe, T., additional, Uoshima, N., additional, Sato, T., additional, Watanabe, R., additional, Kowata, S., additional, Hayakawa, M., additional, Hosoki, T., additional, Ikeda, K., additional, Kobayashi, T., additional, Kakinoki, Y., additional, Nishimoto, T., additional, Takezako, N., additional, Shibayama, H., additional, Takaori, A., additional, Nakamae, H., additional, Kawaguchi, A., additional, Ureshino, H., additional, Sakamoto, J., additional, and Ishida, Y., additional

Published
2019
Full Text
View/download PDF

16. PF623 PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

Author

Iida, S., primary, Sunami, K., additional, Ri, M., additional, Matsumoto, M., additional, Shimazaki, C., additional, Asaoku, H., additional, Shibayama, H., additional, Ishizawa, K., additional, Takamatsu, H., additional, Ikeda, T., additional, Maruyama, D., additional, Kaneko, H., additional, Uchiyama, M., additional, Kiguchi, T., additional, Iyama, S., additional, Murakami, H., additional, Sasaki, T., additional, Tada, K., additional, and Suzuki, K., additional

Published
2019
Full Text
View/download PDF

19. Phase separation dynamics of two-component Bose-Einstein condensates in various optical trap shapes

Author

Shibayama, H., Torii, A., Shibata, K., Eto, Y., Saito, H., and Takuya Hirano

Abstract

It is known theoretically and experimentally that multi-component Bose-Einstein condensates exhibit phase separation and form the spatial structure of spin domains [1], and expected to be a versatile source of intricate non-equilibrium pattern formation dynamics. The formation of various phase separation dynamics by varying potential shapes was theoretically predicted [2]. We investigate the dynamics of phase-separating two-component condensates in various optical trap shapes.

Published
2017

20. Observation of self-organized coherence in dissipative spinor Bose-Einstein condensates

Author

Eto, Y., Shibayama, H., Torii, A., Saito, H., and Takuya Hirano

Abstract

Dissipation is a ubiquitous phenomenon, and it is important to understand its role in non-equilibrium dynamics. In the quantum systems, dissipation often reduce the coherence of the quantum states. But sometimes, it induces completely different effects than the decoherence. For example, strong dissipation can be used to suppress the loss [1] and control the quantum state [2] and quantum phase transition [3].

Published
2017

21. Aspects of CO_2 Uptake in the Crassulacean Acid Metabolism Orchid Phalaenopsis

Author

Ichihashi, S., Higuchi, T., Shibayama, H., Tesima, Y., Nishiwaki, K., Ota, K., Ichihashi, S., Higuchi, T., Shibayama, H., Tesima, Y., Nishiwaki, K., and Ota, K.

Abstract

type:text, Phalaenopsis and its hybrids are the most important orchid pot plant commercially in the world now. Research on photosynthesis gives us practical and useful information for improving cultivation. Although conventional gas-exchange technique has some limitations in the research of a crassulacean acid metabolism plant (CAM), we investigated CO_2 uptake in Phalaenopsis. CO_2 uptake at night (Phase 1) changed with temperature. Maximum CO_2 uptake was observed around 20℃. CO_2 absorption at night increased in proportion to CO_2 concentration. Rate of CO_2 absorption was higher at 20℃ than at 25℃. CO_2 uptake in the late afternoon (Phase 4) showed a maximum around 20℃. CO_2 absorption in Phase 4 increased in proportion to CO_2 concentration but stomata conductance decreased under high CO_2 levels. CO_2 absorption response curve to light intensity in Phase 4 was not saturated till 500 umol.m^<-2>.s^<-1> PPFD when CO_2 level was 2000 ppm, and then the stomata conductance showed very low values. Under various water and humidity condition when Phalaenopsis was irrigated weekly, CO_2 uptake in Phase 1 was the largest at one day before watering, but that of Phase 4 was the largest at one day after watering. Total CO_2 uptake in all Phases was stimulated the most at 70% relative humidity and suppressed drastically at 30% relative humidity. These results indicated that higher relative humidity is likely the most important factor for high CO_2 absorption in Phalaenopsis.

Published
2017

22. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Author

Dimopoulos, Ma, Moreau, P, Palumbo, A, Joshua, D, Pour, L, Hájek, R, Facon, T, Ludwig, H, Oriol, A, Goldschmidt, H, Rosiñol, L, Straub, J, Suvorov, A, Araujo, C, Rimashevskaya, E, Pika, T, Gaidano, G, Weisel, K, Goranova Marinova, V, Schwarer, A, Minuk, L, Masszi, T, Karamanesht, I, Offidani, M, Hungria, V, Spencer, A, Orlowski, Rz, Gillenwater, Hh, Mohamed, N, Feng, S, Chng, Wj, ENDEAVOR Investigators: Leahy, M, Kerridge, I, Durrant, S, Cooney, J, Horvath, N, Rowlings, P, Hahn, U, Fay, K, Renwick, W, Quach, H, Taylor, K, Ho, Sj, Johnston, A, Kasparu, H, Delforge, M, Schots, H, Vekemans, Mc, Offner, F, Wu, Kl, Doyen, C, Bittencourt, R, Duarte, G, Maiolino, A, Schaan, M, Scheliga, A, Zadra, C, Gercheva, L, Mihaylov, G, Grudeva Popova, Z, Sandhu, I, Reiman, A, Kanjeekal, S, Dueck, G, Leblanc, R, Tay, J, White, D, Maisnar, V, Scudla, V, Gregora, E, Hajek, R, Stoppa, Am, Karlin, L, Garderet, L, Fermand, Jp, Lenain, P, Rigaudeau, S, Eveillard, Jr, Escoffre Barbe, M, Knop, S, Kropff, M, Rollig, C, Munder, M, Langer, C, Mugge, Lo, Hanel, M, Niederwieser, D, Dimopoulos, M, Egyed, M, Szomor, A, Borbenyi, Z, Illes, A, Yehuda, Db, Benyamini, N, Nagler, A, Mittleman, M, Izhar, H, Cavo, M, De Fabritiis, P, Petrini, Mario, Foa, R, Gobbi, M, Rossi, G, Guglielmelli, T, Lazzaro, A, Musto, P, Gozzetti, A, Takazako, N, Izumi, T, Chou, T, Ozaki, S, Hatake, K, Suzuki, K, Uike, N, Asakura, S, Kosugi, H, Handa, H, Matsumoto, M, Tobinai, K, Iida, S, Kizaki, M, Miyamoto, T, Shibayama, H, Ando, K, Ishikawa, T, Ishida, T, Sugiura, I, Izutsu, K, Taniwaki, M, Lee, Jh, Kim, K, Kim, Js, Min, Ck, Yoon, Ss, Lee, Jo, Suh, C, Simpson, D, Ganly, P, Blacklock, H, Doocey, R, Chiruka, S, Hellmann, A, Gornik, S, Komarnicki, M, Malgorzata, Calbecka, Grosicki, S, Jurczyszyn, A, Stoia, R, Gheorghita, E, Danaila, Cd, Abdulkadyrov, K, Zaritskiy, A, Andreeva, N, Balakireva, T, Podoltseva, E, Rossiev, V, Pristupa, A, Hsieh, Ws, Gopalakrishnan, Sk, Mistrik, M, Rocafiguera, Ao, Mateos, V, Rubia, J, Dachs, Lr, Sanchez, Jm, Alegre, A, Bargay, J, de Oteyza JP, Martinez, J, Chen, Ty, Lin, Tl, Liu, Jh, Wang, Mc, Yeh, Sp, Huang, Sy, Vinnyk, Y, Kriachok, I, Pylypenko, H, Shparyk, Y, Kaplan, P, Karamanesht, L, Rekhtman, G, Romanyuk, N, Kaiser, M, Mehta, A, Williams, C, Basu, S, Rabin, N, Ramasamy, K, Hunter, H, Tholouli, E, Lebovic, D, Siegel, D, Wang, M, Niesvizky, R, Kovacsovics, T, Hurd, D, Gabrail, N, Matous, J, Pendergrass, K, Agrawal, M, Boccia, R, Chandra, S, Kassim, A, Stanisic, S, Coleman, M, Gersten, T, Braunschweig, I, Chowdhury, S, Sahovic, E., Dimopoulos, Meletios A, Moreau, Philippe, Palumbo, Antonio, Joshua, Dougla, Pour, Ludek, Hájek, Roman, Facon, Thierry, Ludwig, Heinz, Oriol, Albert, Goldschmidt, Hartmut, Rosiñol, Laura, Straub, Jan, Suvorov, Aleksandr, Araujo, Carla, Rimashevskaya, Elena, Pika, Toma, Gaidano, Gianluca, Weisel, Katja, Goranova-Marinova, Vesselina, Schwarer, Anthony, Minuk, Leonard, Masszi, Tamá, Karamanesht, Ievgenii, Offidani, Massimo, Hungria, Vania, Spencer, Andrew, Orlowski, Robert Z, Gillenwater, Heidi H, Mohamed, Nehal, Feng, Shibao, Chng, Wee-Joo, Cavo, M, Laboratory of Molecullar and Cellular Therapy, and Clinical sciences

Subjects
Oncology, Male, Clinical Trial, Phase III, Dexamethasone, Ixazomib, Bortezomib, chemistry.chemical_compound, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Elotuzumab, Multiple myeloma, education.field_of_study, Research Support, Non-U.S. Gov't, Medicine (all), Anemia, Multicenter Study, Survival Rate, 030220 oncology & carcinogenesis, Randomized Controlled Trial, Hypertension, Retreatment, Oligopeptide, Female, Multiple Myeloma, Oligopeptides, Human, medicine.drug, medicine.medical_specialty, Aged, Disease-Free Survival, Follow-Up Studies, Humans, Pneumonia, Thrombocytopenia, Population, Follow-Up Studie, 03 medical and health sciences, Internal medicine, medicine, Comparative Study, education, Antineoplastic Combined Chemotherapy Protocol, business.industry, medicine.disease, Carfilzomib, Surgery, chemistry, Proteasome inhibitor, business, 030215 immunology
Abstract

BACKGROUND: Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. METHODS: In this randomised, phase 3, open-label, multicentre study, patients with relapsed or refractory multiple myeloma who had one to three previous treatments were randomly assigned (1:1) using a blocked randomisation scheme (block size of four) to receive carfilzomib with dexamethasone (carfilzomib group) or bortezomib with dexamethasone (bortezomib group). Randomisation was stratified by previous proteasome inhibitor therapy, previous lines of treatment, International Staging System stage, and planned route of bortezomib administration if randomly assigned to bortezomib with dexamethasone. Patients received treatment until progression with carfilzomib (20 mg/m(2) on days 1 and 2 of cycle 1; 56 mg/m(2) thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1·3 mg/m(2); intravenous bolus or subcutaneous injection) and dexamethasone (20 mg oral or intravenous infusion). The primary endpoint was progression-free survival in the intention-to-treat population. All participants who received at least one dose of study drug were included in the safety analyses. The study is ongoing but not enrolling participants; results for the interim analysis of the primary endpoint are presented. The trial is registered at ClinicalTrials.gov, number NCT01568866. FINDINGS: Between June 20, 2012, and June 30, 2014, 929 patients were randomly assigned (464 to the carfilzomib group; 465 to the bortezomib group). Median follow-up was 11·9 months (IQR 9·3-16·1) in the carfilzomib group and 11·1 months (8·2-14·3) in the bortezomib group. Median progression-free survival was 18·7 months (95% CI 15·6-not estimable) in the carfilzomib group versus 9·4 months (8·4-10·4) in the bortezomib group at a preplanned interim analysis (hazard ratio [HR] 0·53 [95% CI 0·44-0·65]; p

Published
2016

26. Neurological aspects of accidents during bathing

Author

Fukutake, T., primary, Fukumoto, T., additional, Tokumoto, K., additional, Tomura, M., additional, Mitobe, F., additional, Tajima, K., additional, Takeuchi, R., additional, Katada, F., additional, Sato, S., additional, and Shibayama, H., additional

Published
2017
Full Text
View/download PDF

32. Compositional uniformity of a Si 0.5 Ge 0.5 crystal grown on board the International Space Station

Author

Kinoshita, K., primary, Arai, Y., additional, Inatomi, Y., additional, Tsukada, T., additional, Miyata, H., additional, Tanaka, R., additional, Yoshikawa, J., additional, Kihara, T., additional, Tomioka, H., additional, Shibayama, H., additional, Kubota, Y., additional, Warashina, Y., additional, Ishizuka, Y., additional, Harada, Y., additional, Wada, S., additional, Ito, T., additional, Nagai, N., additional, Abe, K., additional, Sumioka, S., additional, Takayanagi, M., additional, and Yoda, S., additional

Published
2015
Full Text
View/download PDF

33. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Author

Hughes, T. P., primary, Hochhaus, A., additional, Kantarjian, H. M., additional, Cervantes, F., additional, Guilhot, F., additional, Niederwieser, D., additional, le Coutre, P. D., additional, Rosti, G., additional, Ossenkoppele, G., additional, Lobo, C., additional, Shibayama, H., additional, Fan, X., additional, Menssen, H. D., additional, Kemp, C., additional, Larson, R. A., additional, and Saglio, G., additional

Published
2014
Full Text
View/download PDF

34. Growth of a Si0.50Ge0.50 crystal by the traveling liquidus-zone (TLZ) method in microgravity

Author

Kinoshita, K., primary, Arai, Y., additional, Inatomi, Y., additional, Tsukada, T., additional, Adachi, S., additional, Miyata, H., additional, Tanaka, R., additional, Yoshikawa, J., additional, Kihara, T., additional, Tomioka, H., additional, Shibayama, H., additional, Kubota, Y., additional, Warashina, Y., additional, Sasaki, Y., additional, Ishizuka, Y., additional, Harada, Y., additional, Wada, S., additional, Harada, C., additional, Ito, T., additional, Takayanagi, M., additional, and Yoda, S., additional

Published
2014
Full Text
View/download PDF

35. Biomedical applications of imidazolium cation-modified iron oxide nanoparticles

Author

Naka, K, Narita, A, Tanaka, H, Chujo, Y, Morita, M, Inubushi, T, Nishimura, I, Hiruta, J, Shibayama, H, Koga, M, Ishibashi, S, Seki, J, Kizaka-Kondoh, S, Hiraoka, M, Naka, K, Narita, A, Tanaka, H, Chujo, Y, Morita, M, Inubushi, T, Nishimura, I, Hiruta, J, Shibayama, H, Koga, M, Ishibashi, S, Seki, J, Kizaka-Kondoh, S, and Hiraoka, M

Published
2008

40. Prognosis of patients with core binding factor acute myeloid leukemia after first relapse

Author

Kurosawa, S., primary, Miyawaki, S., additional, Yamaguchi, T., additional, Kanamori, H., additional, Sakura, T., additional, Moriuchi, Y., additional, Sano, F., additional, Kobayashi, T., additional, Yasumoto, A., additional, Hatanaka, K., additional, Yanada, M., additional, Nawa, Y., additional, Takeuchi, J., additional, Nakamura, Y., additional, Fujisawa, S., additional, Shibayama, H., additional, Miura, I., additional, and Fukuda, T., additional

Published
2013
Full Text
View/download PDF

47. The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up.

Author

Saglio, G., primary, Kantarjian, H., additional, Reiffers, J., additional, Jootar, S., additional, Kalaycio, M. E., additional, Shibayama, H., additional, Fan, X., additional, Gallagher, N. J., additional, Shou, Y., additional, Larson, R. A., additional, Hughes, T. P., additional, and Hochhaus, A., additional

Published
2011
Full Text
View/download PDF

50. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

Author

Kurosawa, S., primary, Yamaguchi, T., additional, Miyawaki, S., additional, Uchida, N., additional, Sakura, T., additional, Kanamori, H., additional, Usuki, K., additional, Yamashita, T., additional, Okoshi, Y., additional, Shibayama, H., additional, Nakamae, H., additional, Mawatari, M., additional, Hatanaka, K., additional, Sunami, K., additional, Shimoyama, M., additional, Fujishima, N., additional, Maeda, Y., additional, Miura, I., additional, Takaue, Y., additional, and Fukuda, T., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results